Treatment of de Quervain's disease:role of conservative management.
This retrospective study compares two methods used to treat de Quervain's disease: splintage with oral non-steroidal anti-inflammatory drugs (NSAIDs) and steroid injection. Patients were separated into three groups based on symptom severity: group I-minimal, group II-mild, and group III-moderate or severe. Three hundred and nineteen wrists in 300 patients were followed from one to six years. Fifteen of 17 patients with minimal symptoms were relieved with splintage and NSAIDs. However, only seven of 20 in Group II and two of eight in Group III treated similarly were relieved. Of the 249 patients in Group III treated with injections, 76% were completely relieved, 7% were improved, and 4% were not improved. We conclude that classification of patients' with de Quervain's disease based on their pre-treatment symptoms may assist surgeons in selecting the most efficacious treatment and in providing prognostic information to their patients.
Lane
L B
LB
Department of Orthopaedic Surgery, Albert Einstein College of Medicine of Yeshiva University, New York, USA.
Boretz
R S
RS
Stuchin
S A
SA
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001623:Betamethasone / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007270:Injections, Intra-Articular; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000008:administration & dosage*; D012189:Retrospective Studies; D013165:Splints; D013717:Tenosynovitis / Q000145:classification / Q000534:rehabilitation*
C018230:betamethasone acetate phosphate; D009288:Naproxen; D001623:Betamethasone